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Abstract 
Background: Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are the two 
most common primary liver cancers, yet there have been no significant advances in effective 
therapeutics. Mesothelin has been reported as a new therapeutic target in various types of 
cancer. Here, we investigated the expression of mesothelin in liver cancer and its potential 
role as a novel therapeutic target for immunotherapy.  
Methods: HCC and CCA specimens were examined by immunohistochemistry for meso-
thelin expression. Protein expression was assessed by immunoblotting and flow cytometry. 
The SS1P immunotoxin targeting mesothelin was evaluated in the well-established CCA cell 
lines HuCCT1, HuH-28, KMBC, KMCH, Mz-ChA-1 and OZ.  
Results: We showed strong immunochemical mesothelin staining in 33% of the surgically 
r e s e c t e d   C C A   s p e c i m e n s   a n d   3   o f   6   C C A   c e l l   l i n e s   ( O Z ,   K M B C   a n d   K M C H ) .   N o   m e s o t h e l i n  
staining was found in HCC or normal liver tissue. Mesothelin was primarily localized to the 
cellular plasma membrane and the mature form (molecular weight, ~40 kDa) was expressed 
a t   a   h i g h   l e v e l   i n   C C A   t i s s u e s .   M o r e o v e r ,   2 2 %   o f   C C A   s p e c i m e n s   h a d   a   h i g h   m e s o t h e l i n  
expression level which was comparable to the CCA cell line models. Interestingly, SS1P 
showed very high and specific growth inhibition when added to mesothelin-expressing CCA 
cells with IC50 values ranging from 0.5 to 11 ng/mL.  
Conclusions:  Mesothelin  is  overexpressed  in  one-third  of  CCA  tissues.  SS1P targeting 
mesothelin reveals a remarkable single agent activity against CCA in vitro. These findings 
indicate a potential for SS1P in the immunotherapeutic treatment of CCA.  
Key  words:  cholangiocarcinoma,  hepatocellular  carcinoma,  bile  duct  carcinoma,  immunotoxin, 
mesothelin, SS1P 
Introduction 
L i v e r   c a n c e r   i s   o n e   o f   t h e   m o s t   c o m m o n   m a l i g-
nancies  worldwide  [1].  Hepatocellular  carcinoma 
( H C C )   a n d   c h o l a n g i o c a r c i n o m a   ( C C A ,   o r   b i l e   d u c t  
c a r c i n o m a )   a r e   t h e   t w o   m o s t   c o m m o n   l i v e r   c a n c e r s   i n  Journal of Cancer 2010, 1 
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h u m a n s .   O f   t h e   s e v e r a l   t y p e s   o f  cancer originating in 
t h e   l i v e r ,   H C C   i s   t h e   m o s t   c o m m o n   f o r m .   C C A   a c-
counts for an estimated 15% of primary liver cancer 
w o r l d w i d e   [ 2 ] .   C C A   i s   a   t e r m   u s e d   b r o a d l y   t o   d e-
scribe  adenocarcinomas  arising  in  both  the  intrahe-
patic and extrahepatic biliary tract. Intrahepatic CCA 
i s   a   p r i m a r y   l i v e r   c a n c e r   t h a t   e x h i b i t s   c h a r a c t e r i s t i c s   o f  
cholangiocyte  differentiation  [3].  The  incidence  and 
mortality rates of CCA have been increasing in West-
e r n   c o u n t r i e s   o v e r   t h e   p a s t   t w o   to  three  decades 
[2,4,5].  In  the  United  State s ,   i n t r a h e p a t i c   C C A   a c-
c o u n t s   f o r   2 , 5 0 0   n e w   c a s e s   o f   l i v e r   c a n c e r   a   y e a r   [ 6 , 7 ] .  
The  etiology  of  most  CCAs  remains  undetermined. 
C C A   i s   r e s p o n s i b l e   f o r   m o r e   t h a n   6 0 %   o f   l i v e r   t u m o r s  
i n   p a r t s   o f   S o u t h e a s t   A s i a ,   e s p e c i a l l y   i n   n o r t h e a s t e r n  
Thailand.  Its  geographic  distribution  worldwide 
coincides  with  endemic  areas  of  liver  flukes  [2]. 
However, there are a number of important risk factors 
associated with CCA in addition to liver flukes. These 
include hepatolithiasis, primary sclerosing cholangi-
tis, and cholodoch a l   c y s t s   [ 2 , 8 ] .   A l t h o u g h   t h e   m a j o r  
etiologies and risk factors for the development of liver 
cancer have been studied for decades, approximately 
9 0 %   o f   C C A   i n   W e s t e r n   c o u n t r i e s   d e v e l o p   i n   t h e   a b-
sence of any known etiology. There have been no sig-
nificant advances in effective therapeutics. Therefore, 
identifying targeted therapy represents a new thera-
peutic approach, but remains a challenge partly due 
t o   a   l a c k   o f   a   g o o d   t h e r a p e u t i c   t a r g e t .   T h u s ,   t h e   i d e n-
tification of novel therapeutic targets in liver cancer is 
of paramount importance.  
 Mesothelin  is  a  tumor  differentiation  antigen 
present  at  low  levels  on  a  restricted  set  of  normal 
adult tissues (e.g. mesothelium), and is expressed at 
h i g h   l e v e l s   i n   m e s o t h e l i o m a s ,   a s   w e l l   a s   o v a r i a n ,  
pancreatic,  and  lung  cancers  [9-11].  The  mesothelin 
gene  encodes  a  71-kDa  precursor  protein  that  is 
processed  to  a 40-kDa  glycosyl-phosphatidylinositol 
(GPI) -anchored protein, the mature mesothelin [12], 
present on the cell surface. 
 The  biological  functions  of  mesothelin  are  un-
defined. A recent study demonstrates that mesothelin 
mediates cell adhesion through an interaction with 
CA125  [13-1 5 ] ,   s u g g e s t i n g   t h a t   t h e r e   m a y   b e   a n   i m-
p o r t a n t   r o l e   f o r   C A 1 2 5   a n d   m e s o t h e l i n   i n   t h e   m e t a s-
tatic spread of cancer in the peritoneal cavity. Serum 
C A 1 2 5   h a s   a l s o   b e e n   e v a l u a t e d   a s   a   d i a g n o s t i c   b i o-
marker for primary liver cancer [16,17]. 
 Shed mesothelin has been evaluated as a diag-
n o s t i c   s e r u m   b i o m a r k e r   f o r   o v a r i a n   c a n c e r   a n d   m e-
sothelioma [18-2 2 ] .   U p o n   e v a l u a t i o n   o f   t h e   i m m u n o-
logical response to mesothelin-expressing tumors, we 
previously  describe  that  the  antibodies  specific  for 
mesothelin are elevated in the sera of patients with 
mesothelioma and epithelial ovarian cancer [23].  
 Mesothelin has also been suggested as a thera-
peutic target in mesothelioma, ovarian, and pancrea-
tic cancers [24]. An anti-mesothelin recombinant im-
m u n o t o x i n ,   S S 1 ( d s F v ) P E 3 8 ,   o r   S S 1 P ,   c o m p o s e d   o f   t h e  
Fv fragment of the antibody SS1 and a truncated form 
of Pseudomonas exotoxin A (PE), has been evaluated in 
Phase I studies [24,25]. Upon binding to mesothelin, 
the  immunotoxin  is  internalized,  undergoes 
processing  in  the  endocytic  compartment  and  the 
immunotoxin  fragment  containing  the 
ADP-r i b o s y l a t i o n   d o m a i n   i s   t r a n s p o r t e d   t o   t h e   e n-
doplasmic  reticulum.  It  is  then  translocated  to  the 
cytosol where it inhibits elongation factor-2 leading to 
inhibition  of  protein  synthesis  and  ultimately  cell 
death.  A  mouse-human  chimeric  IgG  monoclonal 
a n t i b o d y   ( m A b )   b a s e d   o n   t h e   S S 1   F v   h a s   b e e n   d e v e l-
o p e d   a n d   i s   c u r r e n t l y   b e i n g   e v a l u a t e d   i n   a   P h a se  I 
clinical  study  enrolling  patients  with  mesothe-
lin-positive pancreatic, mesothelioma, non-small  cell 
lung and ovarian cancers [26].  
I m m u n o t o x i n   S S 1 P ,   i n   w h i c h   t h e   F v   w a s   o b-
tained from an antibody phage library, binds the N 
terminal (Region I) of cell surface-bound mesothelin 
[15]. Mouse mAbs, MN and MB, were generated in 
mesothelin-deficient  mice  by  DNA  immunizations 
followed by a single boost of a recombinant mesothe-
lin-Fc fusion protein [27]. Both MN and immunotoxin 
S S 1 P   b i n d   t o   R e g i o n   I ,   w h i c h   i s   t h e  most  immuno-
g e n i c   i n   m e s o t h e l i n .   H o w e v e r ,   M B   r e a c t s   w i t h   a n  
unknown epitope and its epitope does not overlap the 
M N   b i n d i n g   s i t e .   T h e   5 B 2   m A b   w a s   g e n e r a t e d   b y  
immunizing  mice  with  a  recombinant  prokaryotic 
fusion  protein  corresponding  to  100  amino  acids 
wh i c h   i s   a l s o   p r e s e n t   i n   t h e   N   t e r m i n a l   R e g i o n   I   o f  
m e s o t h e l i n .   E v e n   t h o u g h   b o t h   M B   a n d   5 B 2   w o r k   f o r  
immunohistochemistry (IHC) [11], 5B2 reacts with the 
b a c t e r i a l   f o r m   o f   m e s o t h e l i n ,   b u t   M B   d o e s   n o t ,   i n d i-
c a t i n g   t h e   b i n d i n g   o f   M B   t o   m e s o t h e l i n   m a y   b e   g l y-
cosylation dependent.  
In  spite  of  the  recent  evidence  showing  meso-
thelin expression in various solid tumors, mesothelin 
has yet to be thoroughly investigated in primary liver 
cancer. Here we characterized the mesothelin expres-
sion in liver cancer by IHC, Western blotting and flow 
cytometry, and investigated mesothelin as a potential 
therapeutic target using the SS1P immunotoxin. We 
demonstrated  that  SS1P  exhibited  remarkably  high 
and  specific  growth  inhibition  against  mesothe-
lin-expressing CCA cells, and should be evaluated as 
a novel therapeutic agent for the immunotherapy of 
CCA. Journal of Cancer 2010, 1 
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Materials and Methods  
Tumor samples  
 Frozen and fixed liver tumor samples were ac-
quired from the Cooperative Human Tissue Network 
(Charlottesville, VA). A set of tissue microarray slides 
containing  samples  of  normal  and  neoplastic  liver 
tissue  were  obtained  from  Pantomics  (Richmond, 
CA).  
 We  followed  the  REMARK  guidelines  [28]  to 
analyze tumor samples. A total of 87 tissue samples 
were analyzed in this study as follows: 10 normal liver 
t i s s u e s ,   6 3   H C C   a n d   1 4   C C A .   T h e   p a t i e n t s ’   a g e   a t   d i-
a g n o s i s   v a r i e d   f r o m   1 8   t o   7 0   y e a r s   ( m e a n   4 7   y r ;   m e-
d i a n   4 7   y r ) .   T h e   t u m o r s   w e r e   s a m p l e d   f r o m   p a t i e n t s   at 
stage I (14%), stage I-II (16%), stage II (36%), stage 
II-I I I   ( 1 6 % ) ,   a n d   s t a g e   I I I   ( 5 % ) ,   w h e r e a s   1 3 %   o f   t h e  
t u m o r s   w e r e   a t   a n   u n k n o w n   s t a g e .   D u p l i c a t e   t i s s u e  
specimens were analyzed for each patient.  
Cell lines  
 A   p a n e l   o f   s i x   h u m a n   H C C   c e l l   l i n e s   w a s  ob-
tained from the National Cancer Institute (NCI) La-
boratory of Human Carcinogenesis, Bethesda, Mary-
land. They include SK-Hep1, HepG2, Hep3B, Huh-1, 
Huh-4, and Huh-7 .   A   p a n e l   o f   t h e   s i x   h u m a n   C C A  
l i n e s   ( H u C C T 1 ,   O Z ,   M z -ChA-1, KMBC, KMCH, and 
HuH-28) was obtained from Dr. Gregory J. Gores of 
the  Mayo  Clinic,  Rochester,  Minnesota.  OVCAR-3 
(human  epithelial  ovarian  cancer  cell  line)  was  ob-
tained  from  American  Type  Culture  Collection 
(ATCC; Manassas, VA). H9 is a transfected A431 hu-
man  epithelial  carcinoma  cell  line  that  stably  ex-
presses  human  mesothelin  [23].  The  cell  lines  were 
c u l t u r e d   i n   R P M I   o r   D M E M   s u p p l e m e n t e d   w i t h   1 0 %  
fetal bovine serum, 100 U/mL penicillin, 0.1 mg/mL 
streptomycin,  and  2  mmol/L  L-glutamine.  In  addi-
tion, recombinant human insulin (10 μg/ml) (Eli Lilly, 
I n d i a n a p o l i s ,   I N )   w a s   a d d e d   t o   a l l   o f   t h e   c u l t u r e s   o f  
the OVCAR-3 cell line. G418 (700 μg/ml) was added 
to all of the cultures of the H9 cell line.  
Immunoblot analysis  
 RIPA buffer (25 mmol/L Tris-HCl (pH 7.6), 150 
mmol/L NaCl, 1% NP-40, 1% sodium deoxycholate, 
0.1% SDS) containing 2% SDS and protease inhibitor 
cocktail tablets (Roche Applied Science, Indianapolis, 
I N )   w a s   u s e d   t o   s o l u b i l i z e   c e l l s   o n   t i s s u e   c u l t u r e  
dishes.  Protein  concentrations  were  determined  by 
the bicinchoninic acid protein assay (Pierce, Rockford, 
IL) according to the manufacturer's protocol. Equiva-
l e n t   a m o u n t s   ( 4 0   µ g   p e r   l a n e )   o f   w h o l e -cell  lysates 
w e r e   s e p a r a t e d   b y   a   4 %   t o   2 0 %   T r i s -glycine 
SDS-PAGE gradient gel and subsequently transferred 
onto nitrocellulose membranes. A lesser amount (2 μg 
p e r   l a n e )   o f   p o s i t i v e   ( H 9 )   a n d   n e g a t i v e   ( A 4 3 1 )   c o n t r o l  
cell lysates were loaded onto the SDS-PAGE gradient 
gel due to very high mesothelin signals in Western 
b l o t s ,   w h i c h   w e r e   d o n e   f o l l o w i n g   t h e   e s t a b l i s h e d  
protocol [11]. Each blot w a s   t r e a t e d   w i t h   1   µ g / m L   o f  
anti-mesothelin  mAb  MN  (Rockland,  Gilbertsville, 
P A )   [ 2 7 ]   o r   a   n e w   r a b b i t   m A b   s p e c i f i c   f o r   m e s o t h e l i n  
(MH and YP, unpublished data). Primary antibodies 
were detected by secondary goat anti-mouse  or  an-
ti-rabbit  antibodies  conjugated  with  horseradish  pe-
roxidase  (Jackson  ImmunoResearch  Laboratories, 
West Grove, PA). Signals were visualized by using the 
Enhanced  Chemiluminescence  Kit  (GE  Healthcare, 
Piscataway, NJ). 
Flow cytometry 
 Flow cytometric analysis was used to measure 
the  antigen  expression  on  cancer  cells.  In  a  typical 
protocol for flow cytometric analysis [11], 5 x 105 cells 
w e r e   i n c u b a t e d   w i t h   2   μ g / m L   o f   a n t i -mesothelin 
m A b   M N   d i l u t e d   w i t h   5 0 0   µ L   o f   P B S   c o n t a i n i n g   5 %  
bovine serum albumin and 0.02% sodium azide. After 
incuba t i o n   f o r   1   h o u r   a t   4 ° C ,   t h e   c e l l s   w e r e   w a s h e d  
o n c e   w i t h   P B S   a n d   i n c u b a t e d   w i t h   a   1 : 2 0 0   d i l u t i o n   o f  
Goat  F(ab’)2 Anti-Mouse Ig’s, R-PE Conjugate (Invi-
t r o g e n / B i o S o u r c e ,   C a r l s b a d ,   C A )   f o r   1   h o u r .   A f t e r  
washing twice with PBS, the cells were suspended in 
0.5 mL PBS, and the fluorescence associated with the 
live cells was measured using a FACSCalibur flow 
cytometer (BD Biosciences, San Jose, CA).  
Immunohistochemistry  
 IHC was conducted following previously estab-
lished  protocols  [11,21,27,29].  In  brief,  after  initial 
deparaffinization/hydration,  antigen  retrieval  was 
p e r f o r m e d   b y   m i c r o w a v i n g   i n   1 0   m M   c i t r a t e   b u f f e r ,  
p H   6 . 0   f o r   5   m i n u t e s   a t   m a x i m u m   p o w e r   a n d   t h e n  
transferring to a pre-warmed steamer for 15 minutes 
to  unmask  the  epitopes.  The  slides  were  incubated 
overnight at 4oC   w i t h   a   p r i m a r y   m o u s e   m A b   a g a i n s t  
mesothelin: 5B2 (Novocastra, Newcastle-upon-Tyne, 
UK, clone; 1:40 dilution) or MB (1 μg/mL) (Rockland) 
[ 2 7 ] .   D e t e c t i o n   w a s   d o n e   u s i n g   t h e   a v i d i n -biotinylated 
peroxidase  method  with  3,3'-diaminobenzidine  te-
trahydrochloride (ABC Kit, Vector, Burlingame, CA). 
Finally,  tissues  were  counterstained  with  hematox-
ylin,  dehydrated,  and  coverslips  were  applied.  Cell 
s t a i n i n g   w a s   e x a m i n e d   o n   a   Z e i s s   A x i o   O b s e r v e r   Z 1  
microscope  (Carl  Zeiss  MicroImaging,  Inc.  Thorn-
wood, NY), and images were collected with Axiovi-
sion software (Carl Zeiss MicroImaging, Inc.).  
Mesothelin  expression  was  characterized  fol-
lowing  previously  established  procedures 
[11,21,27,29]. Mesothelin was detected by staining of Journal of Cancer 2010, 1 
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t h e   s u r f a c e   o f   t u m o r   c e l l s   and the staining graded as 
p o s i t i v e   i f   a t   l e a s t   3 0 %   o f   a c c e s s i b l e   t u m o r   c e l l s   w e r e  
l a b e l e d .   T h i s   c u t o f f   w a s   b a s e d   o n   t h e   r e q u i r e m e n t   f o r  
the clinical trial of the anti-mesothelin immunotoxin, 
S S 1 P ,   f o r   w h i c h   t h e s e   p a t i e n t s   w e r e   b e i n g   s c r e e n e d .  
Similar cutoffs for antigen expression have been used 
for other immunotoxin studies [11,21,27,29]. Howev-
e r ,   i t   i s   p o s s i b l e   t h a t   p a t i e n t s   w h o   w e r e   d e f i n e d   a s  
having  mesothelin-n e g a t i v e   t u m o r s   c o u l d   h a v e   m e-
sothelin  expression  in  a  small  percentage  of  tumor 
cells.  
Cell proliferation assays  
 The growth inhibition of immunotoxin SS1P on 
mesothelin-expressing  liver  cancer  cells  was  deter-
m i n e d   o n   l i v e r   c a n c e r   c e l l   l i n e s   b y   a   W S T -8 cell proli-
feration  assay  as  described  previously  [11].  Cancer 
cells (10,000 per well) in 96-well tissue culture plates 
w e r e   i n c u b a t e d   w i t h   v a r i o u s   c o n c e n t r a t i o n s   o f   S S 1 P  
for 72 hours because all the cancer cell lines examined 
in  this  study  reached  optimal  population  densities 
within 48 to 72 hours.  
Results  
Mesothelin expression in human liver cancers 
 T o   e x a m i n e   t h e   e x p r e s s i o n   o f   m e s o t h e l i n   a n d   i t s  
cellular  localization  in  liver  cancer,  we  examined 
human liver cancer specimens by IHC using the 5B2 
mAb  following  established  protocols  [11,21,27,29]. 
I H C   s t a i n i n g   o f   C C A   s h o w e d   m a i n l y   s t a i n i n g   o f   t h e  
cell membrane with weaker cytoplasmic staining (Fig. 
1 ) .   T h e   i n t e n s i t y   o f   s t a i n i n g   v a r i e d   f r o m   c e l l   t o   c e l l   a n d  
f r o m   t u m o r   t o   t u m o r   b u t   a l l   C C A   t u m o r s   t e s t e d  
s h o w e d   s t a i n i n g   o f   m o r e   t h a n   3 0 %   o f   t h e   t u m o r   c e l l s  
(Fig. 1A and 1B). The desmoplastic stroma around the 
i n v a s i v e   t u m o r   d i d   n o t   s t a i n .   S o m e   s t a i n i n g   o f   t h e  
apical brush border of large bile ducts was also seen. 
In contrast, mesothelin was not detected in both HCC 
and normal liver tissue (Fig. 1C and 1D). Each im-
m u n o r e a c t i v i t y   p a t t e r n   w a s   c o n f i r m e d   b y   d uplicate 
specimens from the same patient.  
 
 
Figure 1. Summary of immunoreactivity patterns in cancer patient specimens. Immunohistochemical evaluation using the 
5B2 mAb showed high (A) and low (B) expression of mesothelin in two representative CCA specimens. No staining was 
found in both HCC (C) and normal liver tissues (D). Each immunoreactvity pattern was confirmed by duplicate specimens 
from the same patient. Scale bar, 100 µm.  Journal of Cancer 2010, 1 
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Characterization of mesothelin protein expres-
sion 
 The mesothelin molecules in liver tumors have 
not been characterized by immunoblotting. Here we 
analyzed the protein expression of mesothelin in 12 
liver  cancer  cell  lines  and  18  tumor  specimens  by 
immunoblotting using the MN mAb. We examined a 
panel  of  12  human  liver  cancer  cell  lines:  6  CCA 
(HuCCT1,  OZ,  Mz-ChA-1,  KMBC,  KMCH,  and 
HuH-28) and 6 HCC (Huh-1, Huh-4, Huh-7, HepG2, 
Hep3B and SK-Hep-1). In Figure 2A, the mesothelin 
mature form  (molecular weight,  ~40 kDa)  was de-
tected at a high level in 50% (3 of 6) CCA cell lines 
(OZ, KMBC and KMCH). Mesothelin expression was 
not  detected  in  the  HCC  cell lines  except  for  weak 
mesothelin expression found in SK-Hep-1.  A  recent 
study  indicated  that  SK-HEP-1   w a s   n o t   a   H C C   c e l l  
l i n e   b e c a u s e   i t   d i d   n o t   h a v e   p r o p e r t i e s   o f   h e p a t o c y t e s  
and was endothelial in origin [30].  
To compare mesothelin levels in CCA with the 
C C A   c e l l   l i n e   m o d e l s ,   w e   o b t a i n e d   a   p a n e l   o f   n i n e  
CCA  and  nine  HCC  specimens  from  major  cancer 
c e n t e r s   i n   t h e   U S A   t h r o u g h   t h e   C o o p e r a t i v e   H u m a n  
T i s s u e   N e t w o r k .   A s   s h o w n   i n   F i g u r e   2 B ,   m a t u r e   m e-
s o t h e l i n   w a s   d e t e c t e d   i n   3 3 %   ( 3   o f   9 )   o f   C C A   s p e c i-
m e n s ;   2 2 %   ( 2   o f   9 )   o f   C C A   s p e c i m e n s   h a d   a   h i g h   m e-
sothelin expression level which is comparable to the 
CCA cell line models (OZ, KMBC and KMCH), and to 
mesothelioma, ovarian cancer and lung adenocarci-
noma [11,25]. Interestingly, one CCA specimen (No. 
333)  had  an  extremely  high  mesothelin  expression 
level with a smear of high molecular weight staining, 
indicating that the mesothelin molecule in this par-
ticular CCA specimen was heavily glycosylated. Me-
sothelin expression was only weakly detected in one 
HCC specimen (No. 610) and its expression level was 
not comparable to the high expression found in CCA 
s p e c i m e n s   ( N o .   3 3 3   a n d   3 3 4 ) .   I n   c o n t r a s t   t o   o u r   p r e-
vious observations in lung adenocarcinoma [11], the 
precursor  form  of  mesothelin  (molecular  weight, 
71-k D a ,   a s   s h o w n   a s   a n   u p p e r   b a n d   i n   t h e   H 9   c o n t r o l ) 
w a s   n o t   d e t e c t a b l e   i n   a n y   o f   t h e   l i v e r   c a n c e r   s p e ci-
mens. We decreased the loading of CCA specimen 333 
with 5-,   1 0 -,   2 0 -f o l d s   l e s s   a m o u n t   o f   p r o t e i n   a n d   f o u n d  
the major band was about 40-kDa (data not shown).  
 
 
Figure 2. Characterization of mesothelin protein expression in liver cancers. (A) Immunoblotting analysis of mesothelin 
proteins in human liver cancer cell lines. Forty µg of w h o l e   c e l l   l y s a t e   w a s   l o a d e d   f o r   e a c h   s a m p l e   e x c e p t   A431 a n d   H 9  (only 
2 μg of total protein was loaded). (B) Immunoblotting analysis of mesothelin proteins in cancer specimens. Forty µg of whole 
cell lysate was loaded for each sample. OVCAR3 (a human ovarian cancer cell line) and H9 (A431.MSLN+) were used as 
positive controls. A431 (MSLN-) was used as a negative control. MSLN: mesothelin (~40 kDa); Precursor: ~71 kDa.  Journal of Cancer 2010, 1 
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 To investigate mesothelin as a potential surface 
target,  we  characterized  cell  surface  expression  of 
mesothelin in six CCA cell lines (HuCCT1, HuH-28, 
KMBC, KMCH, Mz-ChA-1   a n d   O Z )   b y   f l o w   c y t o m e-
t r y .   A s   s h o w n   i n   F i g u r e   3 ,   f o u r   C C A   c e l l   l i n e s   ( O Z ,  
Mz-ChA-1 ,   K M B C   a n d   K M C H )   e x p r e s s e d   m e s o t h e l i n  
p r o t e i n s .   T h e   l e v e l s   o f   c e l l   s u r f a c e   e x p r e s s i o n   were 
consistent with the Western blotting intensities of the 
m a t u r e   f o r m   o f   m e s o t h e l i n   w h e r e a s   M z -ChA-1 had 
r e l a t i v e l y   l o w e r   e x p r e s s i o n   o f   m a t u r e   o r   c e l l   s u r f a c e  
m e s o t h e l i n   a s   c o m p a r e d   t o   O Z ,   K M B C   a n d   K M C H  
(Fig. 2).  
Growth inhibition of immunotoxin SS1P on   C C A  
cell lines  
 To determine if mesothelin could function as a 
new therapeutic target in liver cancer, we tested SS1P, 
an  anti-mesothelin  recombinant  immunotoxin  [24]. 
The growth inhibition of immunotoxin SS1P was de-
t e r m i n e d   o n   s i x   C C A   c e l l   l i n e s   b y   a   W ST cell prolife-
ration assay (Fig. 4). LMB2 was used as a non-specific 
immuntoxin control. LMB2 is a recombinant immu-
notoxin that contains the Fv recognizing the α-subunit 
o f   t h e   I L -2   r e c e p t o r   ( C D 2 5 )   f u s e d   t o   a   3 8 -kDa form of 
PE38. I n   t h e   f o u r   C C A   c a n c e r   c e ll lines with mesothe-
l i n   e x p r e s s i o n   o n   t h e   c e l l   s u r f a c e   ( s h o w n   i n   F i g .   2 ) ,  
OZ,  Mz-ChA-1 ,   K M B C   a n d   K M C H ,   S S 1 P   w a s   v e r y  
active with IC50 values ranging from 0.5 to 11 ng/mL 
(Fig. 4). In the HuCCT1 and HuH-28 cell lines with no 
or  very  low  mesothelin  expression,  no  significant 
growth inhibition (IC50 > 1000 ng/mL) was observed. 
The high growth inhibition was comparable with the 
r e s u l t s   o f   p r e v i o u s   s t u d i e s   i n   m e s o t h e l i o m a   a n d   o v a-
rian cancer [25].  
 
 
 
 
Figure  3.  Flow cytometric analysis of mesothelin protein expression on CCA cells. C e l l s   w e r e   p r o b e d   w i t h   a n   a n-
ti-mesothelin mAb (solid dark line) or an irrelevant isotype mAb control (light gray shading). Each cell line and its GeoMean 
value: HuCCT1 (6.21), HuH-28 (5.54) ,   K M B C   ( 108.74), KMCH (84.63), Mz-ChA-1 (25.19)   a n d   O Z   ( 195.48). GeoMean of 
the isotype antibody control was about 5.0.  Journal of Cancer 2010, 1 
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Figure 4. Inhibition of CCA cell proliferation by SS1P. Cancer cells (10,000 per well) were incubated with various con-
centrations of SS1P. Cell proliferation was measured by a WST assay as described in Materials and Methods. Each point 
r e p r e s e n t s   t h e   m e a n   o f   t r i p l i c a t e   e x p e r i m e n t s   a n d   t h e   e r r o r   b a r s   i n d i c a t e   t h e   s t a n d a r d   d e v i a t i o n .   T h e   d a s h e d   l i n e   i n d i c a t e s  
50% inhibition of cell viability, which is halfway between the level of viability in the absence of toxin and that in the presence 
of 10 µg / m l   o f   c y c l o h e x i m i d e .   E a c h   c e l l   l i n e   a n d   i t s   I C 50 (ng/mL): HuCCT1 (>1000 n g / m l   f o r   b o t h   S S 1 P   a n d   L M B 2 ) ,   H u H -28 
(>1000 ng/ml for both SS1P and LMB2), KMBC (6.8 ng/ml for SS1P; 440.5 n g / m l   f o r   L M B 2 ), KMCH (10.7 ng/ml for SS1P; 
>1000 n g / m l   f o r   L M B 2 ) ,   M z -ChA-1   ( 9 .1 n g / m l   f o r   S S 1 P ; >1000 n g / m l   f o r   LMB2) and OZ (0.5 n g / m l   f o r   S S 1 P ; >1000 n g / m l   f o r  
LMB2). LMB2, a PE immunotoxin control specific for CD25. 
 
Discussion 
There  are  two  major  findings  in  the  present 
study.  First,  we found mesothelin was expressed in 
33%  of  the  surgically  resected  CCA  specimens  and 
also in 3 of 6 CCA cell lines but not in HCC specimens 
a n d   c e l l   l i n e s .   S e c o n d ,   w e   f o u n d   t h a t   b y   t r e a t i n g   t h e  
SS1P  immunotoxin,  the  proliferations  of  CCA  cell 
lines which expressed mesothelin were significantly 
inhibited.  
 Recently,  Valle  et  al.  reported  a  randomized, 
controlled, Phase III trial of 410 patients with locally 
advanced or metastatic CCA, gallbladder cancer, or 
ampullary cancer. In this trial, patients received either 
cisplatin  followed  by  gemcitabine  or  gemcitabine 
a l o n e   f o r   u p   t o   2 4   w e e k s   a t   3 7   c e n t e r s   i n   t h e   U n i t e d  
Kingdom [31]. While the results are encouraging, the 
study strongly suggests that CCA remains very dif-
f i c u l t   t o   c u r e   w i t h   c u r r e n t   m e t h o d s   a n d   m o l ecular 
targeted therapy is urgently needed for this deadly 
disease. 
Ordóñez found by IHC that 37% (7 of 19) of CCA 
showed mesothelin expression and none of HCC ex-
hibited mesothelin expression [32] .   H a s s a n   e t   a l .   d e-
tected  100%  (12  of  12)  mesothelin  expression  in 
c o m m o n   b i l e   d u c t   a d e n o c a r c i n o m a   u s i n g   t h e   5 B 2   a n-
t i b o d y   [ 2 9 ] .   H e r e ,   w e   s h o w e d   b y   I H C   t h a t   t h e   e x p r e s-Journal of Cancer 2010, 1 
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sion of mesothelin was present in 33% of CCA. Nor-
mal  liver  tissues  and  HCC  specimens  showed  no 
mesothelin  expression.  We  also  confirmed  the  IHC 
r e s u l t s   b y   u s i n g   t h e   m A b   M B .   T h e   r e s u l t s   w e r e   f o u n d  
to  be  consistent  although  a  relatively  high 
non-specific background was found (data not shown). 
T h i s   d i f f e r e n c e   m a y   b e   d u e   t o   t h e   f a c t   t h a t   5 B 2   a n d  
M B   b i n d   t w o   d i f f e r e n t   e p i t o p e s   i n   m e s o t h e l i n .   T h e  
bindin g   o f   M B   t o   m e s o t h e l i n   m a y   b e   g l y c o s y l a t i o n  
dependent   a s   p r e v i o u s l y   s u g g e s t e d   [ 2 7 ] .   The present 
I H C   s t u d y   a n d   p r e v i o u s   r e p o r t s   [ 2 9 , 3 2 ] ,   a l l   w i t h   l i-
mited tumor specimens, have suggested a diagnostic 
p o t e n t i a l   o f   m e s o t h e l i n   i n   p r i m a r y   l i v e r   c a n c e r ,   p a r-
ticularly CCA. An examination of additional patient 
studies from various human risk populations includ-
ing specific clinicopathological features and prognos-
tic values will provide further insight into mesothelin 
detection as a general diagnostic tool. 
In the present study, we clearly demonstrate that 
SS1P is very active with IC50 values ranging from 0.5 
to 11 ng/mL on mesothelin-expressing CCA cell lines. 
We have also shown that over 20% of CCA tumors 
have high mesothelin expression with levels compa-
rable  to  the  CC A   c e l l   l i n e   m o d e l s   e v a l u a t e d   i n   t h i s  
w o r k .   S S 1 P   s h o u l d   m e r i t   e v a l u a t i o n   a s   a   n o v e l   t h e r a-
peutic agent for the treatment of primary liver cancer, 
particularly  CCA.  Further  experiments  in  mouse 
m o d e l s   o f   c a n c e r   a n d   h u m a n   c l i n i c a l   t r i a l s   c o u l d  
evaluate this possibility. A clinically relevant mouse 
tumor model to examine the efficacy of SS1P therapy 
is  currently  not  available.  Sirica  and  colleagues  re-
cently established a syngeneic rat model for CCA [33]. 
H o w e v e r ,   i t   i s   n o t   a   s u i t a b l e   m o d e l   f o r   S S 1 P   d u e   t o   t h e  
fact that the SS1 Fv is not cross-reactive with murine 
mesothelin. SS1P has been extensively evaluated in a 
n u d e   m o u s e   m o d e l   i n   w h i c h   a n   A 4 3 1   h u m a n   e p i-
thelial carcinoma cell line transfected with the human 
mesothelin cDNA forms solid tumors [25,34,35]. Fur-
thermore, two Phase I clinical trials of SS1P have been 
c o m p l e t e d   i n   m e s o t h e l i o m a   a n d   o v a r i a n   c a n c e r   p a-
tients [25]. Based on Phase I clinical studies showing 
t h a t   S S 1 P   i s   s a f e   a n d   h a s   a n t i -tumor activity in heavily 
pretreated patients, Phase II studies of SS1P have re-
cently begun. The ongoing clinical trials will help de-
f i n e   t h e   u t i l i t y   o f   m e s o t h e l i n   a s   a   n e w   t a r g e t   f o r   c a n c e r  
therapy. We believe that the  findings in the present 
study demonstrate the potential f o r   a  new clinical trial 
of SS1P for the treatment of CCA. The investigation of 
such applications is a major f o c u s   o f   o u r   c u r r e n t   w o r k .    
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